Clinical impact of time to positivity for Candida species on mortality in patients with candidaemia

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 12, 2013, Pages 2890-2897

  Kim, Si Hyun ^a   Yoon, Young Kyung ^a   Kim, Min Ja ^a   Sohn, Jang Wook ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Antifungal therapy; Blood cultures; Bloodstream infections; Outcomes

Indexed keywords

ANTIFUNGAL AGENT;

ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; CANDIDA; CANDIDEMIA; CASE CONTROL STUDY; CHARLSON COMORBIDITY INDEX; DIAGNOSTIC TEST; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; RETROSPECTIVE STUDY; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; TIME TO POSITIVITY; TREATMENT OUTCOME;

ANTIFUNGAL THERAPY; BLOOD CULTURES; BLOODSTREAM INFECTIONS; OUTCOMES;

AGED; BLOOD; CANDIDA; CANDIDEMIA; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MICROBIOLOGICAL TECHNIQUES; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84887534679     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt256     Document Type: Article

References (31)

1. Fortun J, Martin-Davila P, Gomez-Garcia de la Pedrosa E et al. Emerging trends in candidemia: a higher incidence but a similar outcome. J Infect 2012; 65: 64-70.
2. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-703.
3. Kim SH, Yoon YK, Kim MJ et al. Risk factors for and clinical implications of mixed Candida/bacterial bloodstream infections. Clin Microbiol Infect 2013; 19: 62-8.
4. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
5. Grim SA, Berger K, Teng C et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother 2012; 67: 707-14.
6. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
7. Haimi-Cohen Y, Vellozzi EM, Rubin LG. Initial concentration of Staphylococcus epidermidis in simulated pediatric blood cultures correlates with time to positive results with the automated, continuously monitored BACTEC blood culture system. J Clin Microbiol 2002; 40: 898-901.
8. Kim J, Gregson DB, Ross T et al. Time to blood culture positivity in Staphylococcus aureus bacteremia: association with 30-day mortality. J Infect 2010; 61: 197-204.
9. Peralta G, Rodriguez-Lera MJ, Garrido JC et al. Time to positivity in blood cultures of adults with Streptococcus pneumoniae bacteremia. BMC Infect Dis 2006; 6: 79.
10. Peralta G, Roiz MP, Sanchez MB et al. Time-to-positivity in patients with Escherichia coli bacteraemia. Clin Microbiol Infect 2007; 13: 1077-82.
11. Alvarez R, Vinas-Castillo L, Lepe-Jimenez JA et al. Time to positivity of blood culture association with clinical presentation, prognosis and ESBL-production in Escherichia coli bacteremia. Eur J Clin Microbiol Infect Dis 2012; 31: 2191-5.
12. Liao CH, Lai CC, Hsu MS et al. Correlation between time to positivity of blood cultures with clinical presentation and outcomes in patients with Klebsiella pneumoniae bacteraemia: prospective cohort study. Clin Microbiol Infect 2009; 15: 1119-25.
13. MarraAR, EdmondMB, ForbesBAet al. Timeto blood culture positivityas a predictor of clinical outcome of Staphylococcus aureus bloodstream infection. J Clin Microbiol 2006; 44: 1342-6.
14. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Third Informational Supplement M27-S3. CLSI,Wayne, PA, USA, 2008.
15. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
16. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/ SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
17. Rhee JY, Kwon KT, Ki HK et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock 2009; 31: 146-50.
18. Vincent JL, Moreno R, Takala J et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22: 707-10.
19. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.
20. Garner JS, Jarvis WR, Emori TG et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-40.
21. Lai CC, Wang CY, Liu WL et al. Time to positivity of blood cultures of different Candida species causing fungaemia. J Med Microbiol 2012; 61: 701-4.
22. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
23. Rodriguez D, Park BJ, Almirante B et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect 2007; 13: 788-93.
24. Patel GP, Simon D, Scheetz M et al. The effect of time to antifungal therapy on mortality in candidemia associated septic shock. Am J Ther 2009; 16: 508-11.
25. Klevay MJ, Ernst EJ, Hollanbaugh JL et al. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 2008; 60: 273-7.
26. Parkins MD, Sabuda DM, Elsayed S et al. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007; 60: 613-8.
27. Kludze-Forson M, Eschenauer GA, Kubin CJ et al. The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection. Med Mycol 2010; 48: 436-9.
28. Taur Y, Cohen N, Dubnow S et al. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010; 54: 184-90.
29. Ben-Ami R, Weinberger M, Orni-Wasserlauff R et al. Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol 2008; 46: 2222-6.
30. George BJ, Horvath LL, Hospenthal DR. Effect of inoculum size on detection of Candida growth by the BACTEC 9240 automated blood culture systemusing aerobic andanaerobic media. J Clin Microbiol 2005;43: 433-5.
31. Jung SI, Shin JH, Choi HJ et al. Antifungal susceptibility to amphotericin B, fluconazole, voriconazole, and flucytosine in Candida bloodstream isolates from 15 tertiary hospitals in Korea. Ann Lab Med 2012; 32: 426-8.